Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE:300760)
China · Delayed Price · Currency is CNY 160.46
+0.16 (0.10%)
Apr 16, 2026, 3:11 PM CST
SHE:300760 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 33,172 | 36,624 | 34,875 | 30,354 | 25,258 |
Other Revenue | 110.11 | 101.68 | 56.61 | 11.83 | 11.73 |
| 33,282 | 36,726 | 34,932 | 30,366 | 25,270 | |
Revenue Growth (YoY) | -9.38% | 5.13% | 15.04% | 20.17% | 20.18% |
Cost of Revenue | 13,527 | 13,767 | 12,768 | 10,956 | 8,967 |
Gross Profit | 19,755 | 22,959 | 22,164 | 19,410 | 16,303 |
Selling, General & Admin | 6,696 | 6,883 | 6,534 | 6,122 | 5,105 |
Research & Development | 3,579 | 3,666 | 3,433 | 2,923 | 2,524 |
Other Operating Expenses | -13.4 | -261.66 | -308.79 | -80.36 | -83.14 |
Operating Expenses | 10,456 | 10,586 | 9,903 | 9,001 | 7,539 |
Operating Income | 9,299 | 12,373 | 12,261 | 10,409 | 8,764 |
Interest Expense | -24.02 | -19.41 | -13 | -10.69 | -8.63 |
Interest & Investment Income | 594.86 | 626.87 | 821.64 | 357.91 | 408.14 |
Currency Exchange Gain (Loss) | -113.43 | -51.28 | 119.17 | 171.96 | -227.66 |
Other Non Operating Income (Expenses) | -80.27 | -87.45 | -72.51 | -67.82 | -85.92 |
EBT Excluding Unusual Items | 9,676 | 12,842 | 13,117 | 10,860 | 8,850 |
Gain (Loss) on Sale of Investments | 0.49 | 109.33 | 69.56 | -26.44 | 9.88 |
Gain (Loss) on Sale of Assets | 10.72 | 4.24 | 2.46 | 6.16 | 4.07 |
Asset Writedown | -16.47 | -1.75 | -274.92 | -0.74 | -7.47 |
Legal Settlements | -21.38 | -14.25 | -12.65 | -3.3 | -5.7 |
Other Unusual Items | 24.94 | 80.25 | 109.68 | 117.5 | 166.78 |
Pretax Income | 9,674 | 13,020 | 13,011 | 10,954 | 9,017 |
Income Tax Expense | 1,222 | 1,280 | 1,433 | 1,343 | 1,013 |
Earnings From Continuing Operations | 8,451 | 11,740 | 11,578 | 9,611 | 8,004 |
Minority Interest in Earnings | -315.7 | -71.48 | 3.81 | -3.54 | -2.49 |
Net Income | 8,136 | 11,668 | 11,582 | 9,607 | 8,002 |
Net Income to Common | 8,136 | 11,668 | 11,582 | 9,607 | 8,002 |
Net Income Growth | -30.28% | 0.74% | 20.56% | 20.07% | 20.18% |
Shares Outstanding (Basic) | 1,212 | 1,211 | 1,212 | 1,210 | 1,215 |
Shares Outstanding (Diluted) | 1,212 | 1,211 | 1,212 | 1,210 | 1,215 |
Shares Change (YoY) | 0.03% | -0.04% | 0.11% | -0.36% | -0.07% |
EPS (Basic) | 6.71 | 9.64 | 9.56 | 7.94 | 6.59 |
EPS (Diluted) | 6.71 | 9.63 | 9.56 | 7.94 | 6.59 |
EPS Growth | -30.30% | 0.79% | 20.42% | 20.50% | 20.28% |
Free Cash Flow | 8,107 | 10,473 | 8,373 | 10,226 | 7,596 |
Free Cash Flow Per Share | 6.69 | 8.65 | 6.91 | 8.45 | 6.25 |
Dividend Per Share | 4.380 | 6.270 | 5.800 | 4.500 | 3.500 |
Dividend Growth | -30.14% | 8.10% | 28.89% | 28.57% | 40.00% |
Gross Margin | 59.36% | 62.51% | 63.45% | 63.92% | 64.52% |
Operating Margin | 27.94% | 33.69% | 35.10% | 34.28% | 34.68% |
Profit Margin | 24.45% | 31.77% | 33.16% | 31.64% | 31.66% |
Free Cash Flow Margin | 24.36% | 28.52% | 23.97% | 33.67% | 30.06% |
EBITDA | 10,852 | 13,712 | 13,158 | 11,188 | 9,380 |
EBITDA Margin | 32.61% | 37.34% | 37.67% | 36.84% | 37.12% |
D&A For EBITDA | 1,553 | 1,339 | 896.04 | 779.11 | 616.47 |
EBIT | 9,299 | 12,373 | 12,261 | 10,409 | 8,764 |
EBIT Margin | 27.94% | 33.69% | 35.10% | 34.28% | 34.68% |
Effective Tax Rate | 12.64% | 9.83% | 11.01% | 12.26% | 11.24% |
Revenue as Reported | 33,282 | 36,726 | 34,932 | 30,366 | 25,270 |
Advertising Expenses | 303.72 | 332.39 | 359.41 | 288.69 | 223.68 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.